Warren, S.; Barmpouni, M.; Kossyvaki, V.; Gourzoulidis, G.; Perdrizet, J.
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants. Vaccines 2023, 11, 1369.
https://doi.org/10.3390/vaccines11081369
AMA Style
Warren S, Barmpouni M, Kossyvaki V, Gourzoulidis G, Perdrizet J.
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants. Vaccines. 2023; 11(8):1369.
https://doi.org/10.3390/vaccines11081369
Chicago/Turabian Style
Warren, Sophie, Myrto Barmpouni, Vasiliki Kossyvaki, George Gourzoulidis, and Johnna Perdrizet.
2023. "Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants" Vaccines 11, no. 8: 1369.
https://doi.org/10.3390/vaccines11081369
APA Style
Warren, S., Barmpouni, M., Kossyvaki, V., Gourzoulidis, G., & Perdrizet, J.
(2023). Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants. Vaccines, 11(8), 1369.
https://doi.org/10.3390/vaccines11081369